Emerging drugs for major depressive disorder

An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

(2016) Anita H. Clayton et al.   CNS SPECTRUMS

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

(2016) Robert M. Berman et al.   CNS SPECTRUMS

A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder

(2011) Arif Khan et al.   JOURNAL OF CLINICAL PSYCHIATRY

A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder

(2011) Beth Pangallo et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial

(2011) Pierre Tran et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response

(2011) A. G. Wade et al.   PSYCHOLOGICAL MEDICINE

Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings

(2011) Susanne Graef et al.   PSYCHOPHARMACOLOGY

Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs

(2010) Venkatramanujam Srinivasan et al.   ADVANCES IN THERAPY

Linking Molecules to Mood: New Insight Into the Biology of Depression

(2010) Vaishnav Krishnan et al.   AMERICAN JOURNAL OF PSYCHIATRY

National Trends in the Treatment for Depression From 1998 to 2007

(2010) Steven C. Marcus et al.   ARCHIVES OF GENERAL PSYCHIATRY

Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial

(2010) Wayne C. Drevets et al.   BIOLOGICAL PSYCHIATRY

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

(2010) John H. Krystal et al.   CNS DRUGS

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

(2010) Nizar El-Khalili et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Agomelatine in the Treatment of Major Depressive Disorder

(2010) Stephen M. Stahl et al.   JOURNAL OF CLINICAL PSYCHIATRY

Can We Really Accelerate and Enhance the Selective Serotonin Reuptake Inhibitor Antidepressant Effect?

(2010) Maria J. Portella et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder

(2010) John Zajecka et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Sigma receptors: Potential targets for a new class of antidepressant drug

(2010) James A. Fishback et al.   PHARMACOLOGY & THERAPEUTICS

Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis

(2010) Yann S. Mineur et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Glutamatergic Modulators: The Future of Treating Mood Disorders?

(2010) Carlos Zarate et al.   HARVARD REVIEW OF PSYCHIATRY

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

(2009) Karen A. Tourian et al.   CLINICAL THERAPEUTICS

Triple Reuptake Inhibitors: The Next Generation of Antidepressants

(2009) David Marks et al.   Current Neuropharmacology

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression

(2009) Michael Bauer et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

(2009) Patrice Boyer et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Mirtazapine Versus Other Antidepressants in the Acute-Phase Treatment of Adults With Major Depression

(2009) Norio Watanabe et al.   JOURNAL OF CLINICAL PSYCHIATRY

Gepirone Extended-Release in the Treatment of Adult Outpatients With Major Depressive Disorder

(2009) Robert J. Bielski et al.   JOURNAL OF CLINICAL PSYCHIATRY

Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder

(2009) Michael Bauer et al.   JOURNAL OF CLINICAL PSYCHIATRY

Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder

(2009) Karl Rickels et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

(2009) Ronald N. Marcus et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression

(2009) Sanjay Dubé et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

(2009) Andrea Cipriani et al.   LANCET

The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety

(2009) D.J. Heal et al.   NEUROPHARMACOLOGY

Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157

(2009) Joanna S Fowler et al.   NEUROPSYCHOPHARMACOLOGY

Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials

(2008) D. Deshauer et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder

(2008) Michael R. Liebowitz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system

(2008) Luis San et al.   EUROPEAN PSYCHIATRY

Impact of depression on HIV outcomes in the HAART era

(2008) J. D. Hartzell et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

(2008) GI Papakostas et al.   JOURNAL OF PSYCHOPHARMACOLOGY